BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26032085)

  • 1. Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis.
    Tanaka T; Kurosaki M; Lilly LB; Izumi N; Sherman M
    J Surg Oncol; 2015 Jul; 112(1):72-9. PubMed ID: 26032085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation.
    Xia W; Ke Q; Wang Y; Wang W; Zhang M; Shen Y; Wu J; Xu X; Zheng S
    World J Surg Oncol; 2015 Feb; 13():60. PubMed ID: 25885777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma.
    Piardi T; Gheza F; Ellero B; Woehl-Jaegle ML; Ntourakis D; Cantu M; Marzano E; Audet M; Wolf P; Pessaux P
    Ann Surg Oncol; 2012 Jun; 19(6):2020-6. PubMed ID: 22179632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation.
    Zou WL; Zang YJ; Chen XG; Shen ZY
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.
    Mahmud N; John B; Taddei TH; Goldberg DS
    Clin Transplant; 2019 Jul; 33(7):e13634. PubMed ID: 31177570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of downsizing hepatocellular carcinoma in a liver transplant population.
    Jang JW; You CR; Kim CW; Bae SH; Yoon SK; Yoo YK; Kim DG; Choi JY
    Aliment Pharmacol Ther; 2010 Feb; 31(3):415-23. PubMed ID: 19821808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical behavior of transplantable recurrent hepatocellular carcinoma after curative resection: implications for salvage liver transplantation.
    Lee HS; Choi GH; Joo DJ; Kim MS; Choi JS; Kim SI
    Ann Surg Oncol; 2014 Aug; 21(8):2717-24. PubMed ID: 24916744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience.
    Bonadio I; Colle I; Geerts A; Smeets P; Berardi G; Praet M; Rogiers X; de Hemptinne B; Van Vlierberghe H; Troisi RI
    Clin Transplant; 2015 May; 29(5):425-33. PubMed ID: 25808782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.
    Sapisochin G; Goldaracena N; Astete S; Laurence JM; Davidson D; Rafael E; Castells L; Sandroussi C; Bilbao I; Dopazo C; Grant DR; Lázaro JL; Caralt M; Ghanekar A; McGilvray ID; Lilly L; Cattral MS; Selzner M; Charco R; Greig PD
    Ann Surg Oncol; 2015 Jul; 22(7):2286-94. PubMed ID: 25472651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological differentiation predicts post-liver transplantation survival time.
    Li WX; Li Z; Gao PJ; Gao J; Zhu JY
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of liver transplantation for hepatocellular carcinoma -- a single center experience.
    Iacob R; Iacob S; Gheorghe L; Gheorghe C; Hrehoreţ D; Brașoveanu V; Croitoru A; Herlea V; Popescu I
    Chirurgia (Bucur); 2013; 108(4):446-50. PubMed ID: 23958083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
    Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
    Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
    Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
    Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
    Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.